Our findings, which show significantly improved survival in NF1-mutated CRC cases (p = 0.00001), suggest that NF1 alteration may define a biologically distinct subgroup with differential MAPK pathway engagement and potentially unique therapeutic vulnerabilities. The gene discussed is NF1; the disease is colorectal carcinoma.